EBOLA VACCINE PKG

---Suggested anchor intro---

AS DOCTORS STRUGGLE WITH THE CHALLENGE OF TREATING EBOLA AROUND THE WORLD, RESEARCHERS AT COLORADO STATE UNIVERSITY ARE STARTING PRODUCTION ON A TRIAL VACCINE THAT COULD PROTECT PEOPLE FROM GETTING EBOLA.

PKG RUNS 1:52

SUPERS:

(:02-:07)Colorado State University/Fort Collins, Colorado

(:09-:13)Prof. Dennis Pierro/Dir. BioMARC, Colorado State University

(1:16-1:21)Mike Hooker/Reporting

OUT “…service we provide”

--PKG--

IN THIS LAB AT COLORADO STATE UNIVERSITY RESEARCHERS ARE WORKING ON A VACCINE AGAINST FILOVIRUSES LIKE EBOLA AND MARBURG.

(Prof. Dennis Pierro/Dir. BioMARC, Colorado State University)

With every attempt at producing a vaccine there will be successes and there will be a few failures, and the goal of vaccine development of course is to have one product that comes out and meets the objective of protecting humans.

PROFESSOR DENNIS PIERRO IS THE DIRECTOR OF THIS C.S.U. LAB, CALLED BIOMARC. HERE THEY’RE WORKING UNDER CONTRACT WITH THE DEPARTMENT OF DEFENSE TO MANUFACTURE AN EBOLA VACCINE FOR HUMAN TRIALS INITIALLY TO PROTECT SOLDIERS AGAINST A BIOLOGICAL ATTACK. BUT IF THE VACCINE WORKS IT COULD BE USED TO TREAT THE GENERAL POPULATION.

(Prof. Dennis Pierro/Dir. BioMARC, Colorado State University)

In this case of the DOD they have developed a couple of lead candidates and what that means is that the vaccine that was developed by them has passed certain acceptance criteria for antibody generation or protection against the agent, those sorts of characteristics. There’s a preset number of criteria that the vaccines have to meet, then they decide if this one has the potential to have the same effects in humans and once they get to that point they take the next step and say let’s bring it and do some studies in humans.

DR. PIERRO SAYS THE BIOMARC LAB IS UNIQUE BECAUSE IT’S BEEN APPROVED BY THE F.D.A. AS A CLEAN ROOM PRODUCTION FACILITY RATED AT BIOSAFETY LEVEL 3. THERE’S NO LIVE EBOLA HERE – THAT REQUIRES AN EVEN HIGHER BIOSAFETY LEVEL. INSTEAD, AT BIOMARK THEY’RE USING A NON-INFECTIOUS PROTIEN THAT HOPEFULLY WILL SPUR THE BODY TO GENERATE AN EFFECTIVE EBOLA ANTIBODY IN UPCOMING HUMAN TRIALS.

(Prof. Dennis Pierro/Dir. BioMARC, Colorado State University)

 For human use it really has to be developed in a way that’s safe, effective, and can be characterized easily and the potency is also identified as well. That what the agency is looking for when you do human trials and that’s the service we provide.

---anchor tag---

THE LAB AT COLORADO STATE RECEIVED 2-MILLION DOLLARS TO WORK ON THE VACCINE THROUGH A DEFENSE DEPARTMENT PROGRAM WHICH DEVELOPS AND STOCKPILES VACCINES TO PROTECT SOLDIERS FROM DISEASES THAT CAN BE USED IN BIOLOGICAL WARFARE.

###